Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.

Gi-Hoon NamMinsu KwonHanul JungEunbyeol KoSeong A KimYoonjeong ChoiSu Jeong SongSeohyun KimYeji LeeGi Beom KimJihoon HanJiwan WooYakdol ChoCherlhyun JeongSeung-Yoon ParkThomas M RobertsYong Beom ChoIn-San Kim

Published in: Journal for immunotherapy of cancer (2022)

Our findings suggest that KRAS mutation could be a molecular target for statins to elicit potent tumor-specific immunity.

Keyphrases

wild type
cardiovascular disease
papillary thyroid
squamous cell
type diabetes
anti inflammatory